DexCom's Competitive Landscape: A Deep Dive Into The CGM Market

Dragoljub Bankovic Thesis DexCom, Inc. (NASDAQ:DXCM), is a company focused on the development and commercialization of medical devices for continuous glucose measurement (CGM). Late last month, the company reported Q2 earnings, revealing a decline in new customers as well as a decline in U.S. revenue/customer, which triggered the company to decrease their 2024 revenue guidance from $4.2–4.35 billion (17 — 21% organic growth) to $4.0–4.5 billion (11 — 13% organic growth). To balance the guidance update,  ...